Alger Associates (FBRX) trims Forte Biosciences ownership to a 4.6% stake

Rhea-AI Filing Summary

Alger Associates, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Forte Biosciences, Inc. common stock. Alger reports beneficial ownership of 935,514 shares, representing 4.6% of the class. The firm holds 930,512 shares with sole voting power and 935,514 shares with sole dispositive power, with no shared voting or dispositive power. The securities are held through one or more open-end investment companies or other managed accounts advised by Fred Alger Management, LLC, an investment adviser wholly owned through intermediate holding companies by Alger Associates. Alger indicates it now holds 5 percent or less of the class.

Key Figures

Beneficial ownership: 935,514 shares Percent of class: 4.6% Sole voting power: 930,512 shares +3 more

6 metrics

Beneficial ownership 935,514 shares Amount of Forte Biosciences common stock beneficially owned by Alger Associates

Percent of class 4.6% Reported percentage of Forte Biosciences common stock class owned

Sole voting power 930,512 shares Shares of Forte Biosciences over which Alger has sole voting power

Shared voting power 0 shares Shares over which Alger has shared voting power

Sole dispositive power 935,514 shares Shares over which Alger has sole power to dispose or direct disposition

Shared dispositive power 0 shares Shares over which Alger has shared power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, dispositive power, open-end investment companies, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 935,514"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 930,512.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 935,514.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

open-end investment companies financial

"The securities reported herein are beneficially owned by one or more open-end investment companies"

registered investment adviser financial

"clients of Fred Alger Management, LLC ("FAM"), a registered investment adviser."

A registered investment adviser (RIA) is a firm or individual legally registered with regulators to give personalized investment advice and manage clients' money, with a duty to put clients’ interests ahead of their own. Think of an RIA as a licensed financial guide who must disclose fees, conflicts and how they are paid; that transparency and legal duty matter to investors because it reduces the risk of hidden costs or biased recommendations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:06 PM Accepted by SEC EDGAR 08/07/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What percentage of Forte Biosciences (FBRX) does Alger Associates currently report owning?

Alger Associates reports beneficial ownership of 4.6% of Forte Biosciences’ common stock. This corresponds to 935,514 shares and is disclosed as ownership of 5 percent or less of the class under Item 5.

How many Forte Biosciences (FBRX) shares does Alger Associates beneficially own?

Alger Associates beneficially owns 935,514 shares of Forte Biosciences common stock. Of these, 930,512 shares carry sole voting power and all 935,514 shares are subject to sole dispositive power, with no shared powers reported.

Does Alger Associates share voting power over its Forte Biosciences (FBRX) holdings?

No. Alger Associates reports sole voting power over 930,512 shares and shared voting power over 0 shares of Forte Biosciences. It also reports sole dispositive power over 935,514 shares and no shared dispositive power.

Through which entities does Alger Associates hold its Forte Biosciences (FBRX) position?

The Forte Biosciences shares are beneficially owned by open-end investment companies or other managed accounts that are clients of Fred Alger Management, LLC, a registered investment adviser wholly owned indirectly by Alger Associates.

What type of filing did Alger Associates make regarding Forte Biosciences (FBRX)?

Alger Associates submitted an Amendment No. 9 to Schedule 13G for Forte Biosciences common stock. The filing updates its beneficial ownership information and confirms that it now owns 5 percent or less of the class.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

34962G208

(CUSIP Number)

07/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

Alger Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 930,512.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 935,514.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

935,514.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247
Item 2.
(a)	Name of person filing: Alger Associates, Inc.
(b)	Address or principal business office or, if none, residence: 100 Pearl Street, 27th Floor, New York, NY 10004
(c)	Citizenship: New York
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 935,514
(b)	Percent of class: 4.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 930,512
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 935,514
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC ("FAM"), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC ("AGH"), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit A.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alger Associates, Inc.

Signature:	/s/ Hal Liebes
Name/Title:	Hal Liebes / Secretary
Date:	08/07/2026